Corneal Graft Rejection - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：43頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Corneal Graft Rejection - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Corneal Graft Rejection - Pipeline Review, H1 2014’, provides an overview of the Corneal Graft Rejection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Corneal Graft Rejection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Corneal Graft Rejection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Corneal Graft Rejection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Corneal Graft Rejection - Pipeline Review, H1 2014’, provides an overview of the Corneal Graft Rejection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Corneal Graft Rejection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Corneal Graft Rejection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Corneal Graft Rejection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Corneal Graft Rejection Overview 6
Therapeutics Development 7
Pipeline Products for Corneal Graft Rejection - Overview 7
Pipeline Products for Corneal Graft Rejection - Comparative Analysis 8
Corneal Graft Rejection - Therapeutics under Development by Companies 9
Corneal Graft Rejection - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Corneal Graft Rejection - Products under Development by Companies 14
Corneal Graft Rejection - Companies Involved in Therapeutics Development 15
Oxford BioMedica plc 15
FibroGen, Inc. 16
EyeGate Pharmaceuticals, Inc. 17
Gene Signal International SA 18
Icon Bioscience, Inc. 19
Corneal Graft Rejection - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FG-5016 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug For Cornea Transplant Rejection - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
EncorStat - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dexamethasone acetate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Stromal Cell Therapy For Corneal Graft Rejection - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Corneal Graft Rejection - Recent Pipeline Updates 37
Corneal Graft Rejection - Product Development Milestones 40
Featured News & Press Releases 40
Apr 23, 2014: European Commission Grants Orphan Drug Designation to Soliris (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation 40
Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Corneal Graft Rejection, H1 2014 7
Number of Products under Development for Corneal Graft Rejection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Corneal Graft Rejection - Pipeline by Oxford BioMedica plc, H1 2014 15
Corneal Graft Rejection - Pipeline by FibroGen, Inc., H1 2014 16
Corneal Graft Rejection - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2014 17
Corneal Graft Rejection - Pipeline by Gene Signal International SA, H1 2014 18
Corneal Graft Rejection - Pipeline by Icon Bioscience, Inc., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H1 2014 37
List of Figures
Number of Products under Development for Corneal Graft Rejection, H1 2014 7
Number of Products under Development for Corneal Graft Rejection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Corneal Graft Rejection Overview 6
Therapeutics Development 7
Pipeline Products for Corneal Graft Rejection - Overview 7
Pipeline Products for Corneal Graft Rejection - Comparative Analysis 8
Corneal Graft Rejection - Therapeutics under Development by Companies 9
Corneal Graft Rejection - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Corneal Graft Rejection - Products under Development by Companies 14
Corneal Graft Rejection - Companies Involved in Therapeutics Development 15
Oxford BioMedica plc 15
FibroGen, Inc. 16
EyeGate Pharmaceuticals, Inc. 17
Gene Signal International SA 18
Icon Bioscience, Inc. 19
Corneal Graft Rejection - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FG-5016 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug For Cornea Transplant Rejection - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
EncorStat - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dexamethasone acetate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Stromal Cell Therapy For Corneal Graft Rejection - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Corneal Graft Rejection - Recent Pipeline Updates 37
Corneal Graft Rejection - Product Development Milestones 40
Featured News & Press Releases 40
Apr 23, 2014: European Commission Grants Orphan Drug Designation to Soliris (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation 40
Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Corneal Graft Rejection, H1 2014 7
Number of Products under Development for Corneal Graft Rejection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Corneal Graft Rejection - Pipeline by Oxford BioMedica plc, H1 2014 15
Corneal Graft Rejection - Pipeline by FibroGen, Inc., H1 2014 16
Corneal Graft Rejection - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2014 17
Corneal Graft Rejection - Pipeline by Gene Signal International SA, H1 2014 18
Corneal Graft Rejection - Pipeline by Icon Bioscience, Inc., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H1 2014 37
List of Figures
Number of Products under Development for Corneal Graft Rejection, H1 2014 7
Number of Products under Development for Corneal Graft Rejection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
